A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
Launched by VERASTEM, INC. · Nov 5, 2008
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with advanced non-hematologic malignancies.
- • Adequate organ function, including bilirubin less than 1.5 x ULN, and ECOG (Eastern Cooperative Oncology Group) performance status of 0-2.
- Exclusion Criteria:
- • Clinically significant gastrointestinal abnormalities, requirement for systemic anticoagulants or potent CYP 2C8 inhibitors, and history of clinically significant cardiac or pulmonary disorders
About Verastem, Inc.
Verastem, Inc. is a biopharmaceutical company focused on advancing innovative therapies for cancer treatment. With a commitment to addressing unmet medical needs, Verastem leverages its expertise in oncology to develop targeted therapies that aim to improve patient outcomes. The company is dedicated to rigorous clinical research and collaboration with healthcare providers, striving to bring new hope to patients affected by various forms of cancer. Through its pioneering efforts, Verastem seeks to transform the landscape of cancer care with effective and well-tolerated treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Nashville, Tennessee, United States
Toronto, Ontario, Canada
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials